David Geffen School of Medicine at UCLA

Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Retrieved on: 
Monday, October 23, 2023

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented new data from four scientific abstracts during the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting and Postgraduate Course.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented new data from four scientific abstracts during the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting and Postgraduate Course.
  • “The data presented at ACG peel back the many layers of these disorders’ impact.
  • While pain is usually associated with IBS-C, it also can be experienced by those with CIC and both patient groups can be affected by anal/rectal-related adverse consequences.
  • Non-D-IBS and CIC cases had higher costs versus controls on both a per-patient and a per-utilization basis.

Nanoscope Therapeutics Announces Presentations in Upcoming Conferences

Retrieved on: 
Monday, October 2, 2023

Details for the presentations are below:

Key Points: 
  • Details for the presentations are below:
    Panel Discussion: Visual Preservation in Retinal Diseases: Will Gene Therapy Make a Dent?
  • On the panel, Dr. Mohanty will highlight gene-agnostic approaches that have the potential to affect large patient populations with retinal degeneration diseases.
  • In this session, Dr. Mohanty will highlight Nanoscope's Multi-Characteristic Opsin platform and recent clinical data from the clinical trials for patients with advanced retinitis pigmentosa and Stargardt disease.
  • Session Details: Available as an audio-narrated free paper viewable at the event or on the virtual congress platform at 4:00 p.m. CEST on October 5, 2023.

Lundquist Investigator Dr. Harry Rossiter Awarded $3.8 Million NIH Grant To Develop the Next-Generation Cardiopulmonary Exercise Test

Retrieved on: 
Wednesday, September 20, 2023

The R01 is the most prestigious and competitive NIH grant (only 10% are funded) awarded to biomedical researchers.

Key Points: 
  • The R01 is the most prestigious and competitive NIH grant (only 10% are funded) awarded to biomedical researchers.
  • Dr. Rossiter’s research team at TLI has developed the next generation of the cardiopulmonary exercise test; the standard clinical test to investigate exercise intolerance.
  • “This research builds on what Lundquist Institute investigators developed fifty years ago,” said David I. Meyer, TLI President and CEO.
  • “This next-generation CPET being developed by Dr. Rossiter and his team will become the new gold standard for clinical investigation of exercise intolerance.”

Dr. Charmaine Lok and Dr. Allen R. Nissenson Join PatenSee's Scientific Advisory Board

Retrieved on: 
Wednesday, September 20, 2023

OR YEHUDA, Israel, Sept. 20, 2023 /PRNewswire/ -- Dr. Charmaine Lok is the new Chairperson of the PatenSee Scientific Advisory Board. The company also announced today that Dr. Allen R. Nissenson has joined the company as a strategic advisor. PatenSee is developing a contactless imaging system to provide rapid vascular access monitoring for hemodialysis patients.

Key Points: 
  • OR YEHUDA, Israel, Sept. 20, 2023 /PRNewswire/ -- Dr. Charmaine Lok is the new Chairperson of the PatenSee Scientific Advisory Board.
  • The company also announced today that Dr. Allen R. Nissenson has joined the company as a strategic advisor.
  • I am delighted to join PatenSee as the chairperson of its Scientific Advisory Board and look forward to guiding this technology's further development to rapidly make it available for improving patient outcomes," said Dr. Lok.
  • Dr. Nissenson currently serves on the Board of Directors of Elicio Therapeutics, Rockwell Medical, Innocura Nephrology and Diality Inc.

Los Angeles Center for Ear, Nose, Throat and Allergy Welcomes Laryngologist, Dr. Abie Mendelsohn to Practice

Retrieved on: 
Tuesday, August 1, 2023

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- The Los Angeles Center for Ear, Nose, Throat, and Allergy (LA CENTA) has announced the addition of Dr. Abie Mendelsohn, M.D., F.A.C.S. to their practice. Dr. Mendelsohn is a fellowship trained laryngologist who offers a university level, minimally invasive surgical approach to head and neck surgery.

Key Points: 
  • LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- The Los Angeles Center for Ear, Nose, Throat, and Allergy (LA CENTA) has announced the addition of Dr. Abie Mendelsohn, M.D., F.A.C.S.
  • Dr. Mendelsohn is a fellowship trained laryngologist who offers a university level, minimally invasive surgical approach to head and neck surgery.
  • "We could not be more excited to welcome Dr. Mendelsohn to our practice," said LA CENTA Founder and CEO Dr. Geoff Trenkle, D.O.
  • Dr. Mendelsohn has also served as a Staff Surgeon in the Division of Head & Neck Surgery at the Veterans Affairs (VA) Medical Center of Greater Los Angeles and Volunteer Staff Surgeon at Walter Reed National Military Medical Center.

The Lundquist Institute Receives Gift from the Samberg Foundation to Study the Use of Psilocybin in Alleviating Demoralization and Psychological Distress in Palliative Care

Retrieved on: 
Monday, July 24, 2023

Los Angeles, California, July 24, 2023 (GLOBE NEWSWIRE) -- The Joe & Sandy Samberg Foundation has made a gift of $300,000 to The Lundquist Institute to study the use of psilocybin in alleviating demoralization and the psychological distress associated with life-threatening illness in palliative care.

Key Points: 
  • Los Angeles, California, July 24, 2023 (GLOBE NEWSWIRE) -- The Joe & Sandy Samberg Foundation has made a gift of $300,000 to The Lundquist Institute to study the use of psilocybin in alleviating demoralization and the psychological distress associated with life-threatening illness in palliative care.
  • The gift will facilitate an FDA-approved multi-site clinical trial.
  • Our earlier research with psilocybin suggests that improved mood and lessening of death anxiety and demoralization can occur, even in the context of extreme and dire health circumstances.
  • We are very thankful to the Samberg Foundation for this gift, which allows us to continue to explore this promising therapy in FDA-clinical trials.”

Lundquist Institute Investigator Dr. Virender Rehan and Advent Therapeutics Awarded $3 Million NIH Small Business Innovation Research Grant for Life-saving Premature Infant Research

Retrieved on: 
Tuesday, July 18, 2023

The funding will directly support the groundbreaking work of Dr. Rehan Virender, which focuses on developing a first-of-its-kind aerosolized vitamin A formulation.

Key Points: 
  • The funding will directly support the groundbreaking work of Dr. Rehan Virender, which focuses on developing a first-of-its-kind aerosolized vitamin A formulation.
  • This innovative treatment aims to counteract Bronchopulmonary Dysplasia (BPD), a life-threatening condition affecting premature infants, with an eye towards commercialization by 2025.
  • Each year, BPD, the leading severe complication in premature infants, impacts an estimated 20,000-30,000 newborns in the United States.
  • The aerosolized vitamin A therapy under development by Dr. Rehan and Advent Therapeutics represents a pivotal advancement in neonatal care.

Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy

Retrieved on: 
Tuesday, July 18, 2023

DOYLESTOWN, Pa., July 18, 2023 (GLOBE NEWSWIRE) -- Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant.

Key Points: 
  • DOYLESTOWN, Pa., July 18, 2023 (GLOBE NEWSWIRE) -- Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant.
  • This grant allows the Company to position its novel aerosolized vitamin A formulation for commercialization in 2025 to prevent Bronchopulmonary Dysplasia (BPD).
  • With this grant, the Company has now received in excess of $6 million from NIH for its neonatal programs.
  • Dr. Virender continued, “I am extremely pleased to be involved in developing Advent’s novel form of inhalable vitamin A therapy.

Dr. SriniVas R. Sadda Named 2023-2024 ARVO President Elect

Retrieved on: 
Tuesday, June 27, 2023

PASADENA, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Doheny Eye Institute , one of the nation’s leading vision research institutions, announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 Annual Meeting in New Orleans, La.

Key Points: 
  • PASADENA, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Doheny Eye Institute , one of the nation’s leading vision research institutions, announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 Annual Meeting in New Orleans, La.
  • Dr. Sadda has been a member of ARVO for a number of years, and served on the Board of Trustees for the past three years.
  • “We are eager to see Dr. Sadda step into his new role of ARVO President Elect, as he has already proven to be an integral member of our board over the last few years,” said J.
  • “Being selected to serve as President Elect, and ultimately President in another year, is a tremendous honor and career highlight.

Innova Vascular Earns FDA Clearance for Two New Thrombectomy Devices: Laguna Clot Retriever™ System and Malibu Aspiration Catheter™ System

Retrieved on: 
Wednesday, June 7, 2023

The two new devices are collectively known as the Laguna Thrombectomy System.

Key Points: 
  • The two new devices are collectively known as the Laguna Thrombectomy System.
  • The Malibu Aspiration Catheter System offers excellent navigability and ease of use, with the ability for operators of all skill levels to remove clots efficiently.
  • "The Laguna Thrombectomy System offers an innovative solution to treat a wide range of clots in the peripheral vasculature."
  • The System offers a comprehensive range of sizes of the Malibu Aspiration Catheter as well as the Laguna Clot Retriever.